Poloxime - Polo-like Kinase (PLK) 抑制剂 - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPoloximeCat. No.: HY-77195CAS No.: 17302-61-3分式: CHNO分量: 179.22作靶点: Polo-like Kinase (PLK)作通路: Cell Cycle/DNA Damage储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (557.97 mM)H2O

2、: 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (13.95 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (13.95 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (13.95 mM); Cl

3、ear solutionBIOLOGICAL ACTIVITY物活性 Poloximepoloxin 的解产物，为 ATP 竞争性的 Plk1 抑制剂，可以适当地抑制 Plk1 的活性。IC50 & Target PLK1体外研究 Poloxime (100 M) inhibits phosphopeptide binding to polo-box domain (PBD) of polo-like kinase 1 (Plk1) 2.REFERENCES1. Liu M, et al. Identification of indole-3-carboxylic acids as non-A

4、TP-competitive Polo-like kinase 1 (Plk1) inhibitors. Bioorg Med ChemLett. 2015 Feb 1;25(3):431-4.2. Yin Z, et al. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. ACS Chem Biol. 2013 Feb15;8(2):303-8.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;Fax: 021